Send PM
Followers 28
Posts 4196
Boards Moderated 0
Alias Born 03/20/2011


Re: Solarfuture post# 71

Tuesday, 11/22/2022 8:46:38 PM

Tuesday, November 22, 2022 8:46:38 PM

Post# of 92
Interesting info here regarding a Phase 2 trial over at PDS Biotech:

Excerpt 1

"As previously reported, data confirm PDS0101 treatment activates HPV16-specific CD8+ T cells. This increase was not seen in patients who did not receive PDS0101. The increase in HPV16-specific T cells generated by the treatment is positively correlated with tumor cell death, suggesting cytotoxic CD8+ T cells are important mediators of antigen-specific immunity."

Remember IMTX held back the results from the IMA203 +CD8 part of the trial. Might be interesting results - also Opdivo + IMA 203 results ( BMS) held back.

IMTX trials sre still in an early phase, imo. TCR-T category still early as well, imo.

Not sure if IMTX will be presenting at the ASH. TScan is and is also in the TCR-T category with a very strategic approach, imo.

Day Range:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IMTX News